Trial Profile
A Phase I, Randomized, Multiple-Dose Study to Evaluate the Pharmacokinetic Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Samatasvir (Primary) ; Simeprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme Corp.
- 28 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 21 Mar 2013 Status changed from planning to recruiting.